This methodological review provides essential guidance on adapting standard human platelet aggregometry techniques for use with mouse platelets in basic cardiovascular and hematology research.
Answers are grounded in this paper and cite their sources.
Requires method adaptations for mouse platelet assays; extends gold-standard testing to genetic models while leaving standardization unresolved.
Light transmission aggregometry and lumi-aggregometry are the gold standard platelet assays both clinically and for basic research. The availability of different strains of genetically modified mice and mouse models of human disease means that often laboratories need to use mouse platelets in these assays. Overall, performing aggregometry and lumi-aggregometry with mouse platelets is similar to with human platelets, although methods need be adapted to accommodate their small size, reduced blood volume, and different protein levels. This review aims to highlight these key considerations when planning aggregometry experiments with mouse platelets. These include the method of taking blood, including the use of anticoagulants, as well as the method of platelet preparation, and how to maximize yields. This review also covers how to maximize the number of aggregations that can be performed, both by understanding the minimum requirements of your aggregometer, or by considering new approaches. These include employing high throughput plate-based aggregometry (Optimul), or the use of TPO-mimetics to stimulate platelet production in mice to boost their platelet counts. Finally, phenotypic differences between mouse and human platelets, such as protein expression or sensitivity to agonists are discussed as an important consideration when planning experiments.
No takes yet. Share an insight, caveat, or question.
Craig E. Hughes (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: